Looking to the future treatment landscape for relapsed/refractory multiple myeloma, Surbhi Sidana, MD, highlights ongoing research and discusses potential opportunities for improving care.
Case: A 60-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma
Clinical Presentation:
Prior Treatments:
Follow up and Clinical Workup at Relapse:
Video content above is prompted by the following questions:
MRD Negativity Improves With D-VRd in Newly Diagnosed, Transplant-Eligible Myeloma
September 6th 2024Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More